Literature DB >> 17692439

Long-term persistence of antibodies after one or two doses of MMR-vaccine.

Corinne Vandermeulen1, Roelants Mathieu, Leroux-Roels Geert, Van Damme Pierre, Hoppenbrouwers Karel.   

Abstract

Outbreaks of measles, mumps and rubella have occurred recently despite long-standing mass immunization with MMR. Antibody titres for measles, mumps and rubella of 160 students (17-23 years) with proof of at least one MMR-vaccine were studied according to the number of MMR-vaccines received. The proportion of subjects with positive antibody titres was significantly higher in those who received two vaccines against measles (77.1% versus 58.7%, p=0.05), mumps (67.5% versus 55.6%, p=0.009) and rubella (99.2% versus 71.4%, p=0.008). Comparable significant trends were seen for GMTs for measles and mumps. A similar non-significant trend was noted for rubella.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17692439     DOI: 10.1016/j.vaccine.2007.07.008

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Vaccination in secondary school students expedites rubella control and prevents congenital rubella syndrome.

Authors:  Hanqing He; Rui Yan; Xuewen Tang; Yang Zhou; Xuan Deng; Shuyun Xie
Journal:  BMC Infect Dis       Date:  2016-11-30       Impact factor: 3.090

2.  Maternal mumps antibodies in a cohort of children up to the age of 1 year.

Authors:  E Leuridan; N Goeyvaerts; N Hens; V Hutse; P Van Damme
Journal:  Eur J Pediatr       Date:  2012-03-07       Impact factor: 3.183

3.  Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel.

Authors:  Hagai Levine; Salman Zarka; Omer E Ankol; Vladi Rozhavski; Nadav Davidovitch; Yair Aboudy; Ran D Balicer
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Seroepidemiology of mumps in the general population of Jiangsu province, China after introduction of a one-dose measles-mumps-rubella vaccine.

Authors:  Yuanbao Liu; Ying Hu; Xiuying Deng; Zhiguo Wang; Peishan Lu; Fubao Ma; Minghao Zhou; Pei Liu; Jie Min
Journal:  Sci Rep       Date:  2015-10-01       Impact factor: 4.379

5.  Detection of mumps virus-specific memory B cells by transfer of peripheral blood mononuclear cells into immune-deficient mice.

Authors:  Corinne Vandermeulen; Lieven Verhoye; Sunil Vaidya; Frédéric Clement; Kevin E Brown; Karel Hoppenbrouwers; Geert Leroux-Roels
Journal:  Immunology       Date:  2010-06-25       Impact factor: 7.397

6.  Susceptibility to measles, mumps, and rubella in 5-year-old children in Flanders, Belgium.

Authors:  E Leuridan; K Maertens; M Wautier; V Hutse; H Theeten
Journal:  Eur J Pediatr       Date:  2015-01-13       Impact factor: 3.183

7.  Seroprevalence and Determinants Associated with Mumps Antibodies after 20 Years of MMR Vaccination in Urban Area of Shanghai, China.

Authors:  Hong Pang; Yibiao Zhou; Wensui Zhao; Qingwu Jiang
Journal:  Int J Environ Res Public Health       Date:  2018-09-23       Impact factor: 3.390

8.  Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination.

Authors:  Chung-Jong Kim; Ji-Yun Bae; Kang-Il Jun; Hae-Sun Chung; Aeyeon Kim; Jihee Kim; Hee-Jung Son; Miae Lee; Hee-Jung Choi
Journal:  Vaccines (Basel)       Date:  2021-05-12

9.  Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques.

Authors:  Clarisse Lorin; Lawrence Segal; Johann Mols; Danielle Morelle; Patricia Bourguignon; Olga Rovira; Pascal Mettens; Jérémy Silvano; Nicolas Dumey; Frédérick Le Goff; Marguerite Koutsoukos; Gerald Voss; Frédéric Tangy
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-09-16       Impact factor: 3.000

10.  Seroprevalence of mumps in The Netherlands: dynamics over a decade with high vaccination coverage and recent outbreaks.

Authors:  Gaby Smits; Liesbeth Mollema; Susan Hahné; Hester de Melker; Irina Tcherniaeva; Sandra Waaijenborg; Rob van Binnendijk; Fiona van der Klis; Guy Berbers
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.